SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Quint Jennifer K.)
 

Sökning: WFRF:(Quint Jennifer K.) > SABINA :

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004744naa a2200469 4500
001oai:DiVA.org:uu-425647
003SwePub
008201123s2020 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4256472 URI
0247 a https://doi.org/10.1007/s12325-020-01233-02 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Janson, Christeru Uppsala universitet,Lung- allergi- och sömnforskning4 aut0 (Swepub:uu)chrisjn
2451 0a SABINA :b An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries
264 c 2020-01-24
264 1b Springer Science and Business Media LLC,c 2020
338 a electronic2 rdacarrier
520 a IntroductionGlobally, individuals with asthma tend to overrely on short-acting β2-agonists (SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying inflammation. Such relief-seeking behavior has been reinforced by long-standing treatment guidelines, which until recently recommended SABA-only use for immediate symptom relief. We aimed to describe the current burden of SABA use among European individuals with asthma within the SABA use IN Asthma (SABINA) program.MethodsPrescription and/or dispensing data during 2006–2017 from electronic medical records and/or national patient registries in the United Kingdom (UK), Germany, Italy, Spain, and Sweden were analyzed. Individuals aged at least 12 years old with a current asthma diagnosis and no other chronic respiratory conditions were included. Asthma treatment step and severity were based on treatment guidelines in use in each individual country. The proportion of individuals prescribed SABA was measured during a 12-month period. SABA overuse was defined as at least three SABA canisters per year.ResultsMore than one million individuals with asthma were included across five European countries. Overall, the majority of individuals were over 45 years of age, except in Sweden (mean age 27.6 years) where individuals aged over 45 years were excluded to avoid a potential chronic obstructive pulmonary disease co-diagnosis. The study population was predominantly female (55–64%), except in the UK (46%). The prevalence of SABA overuse was 9% in Italy, 16% in Germany, 29% in Spain, 30% in Sweden, and 38% in the UK. In the UK, SABA overuse was greater in individuals with moderate-to-severe asthma versus individuals with mild asthma (58% versus 27%, respectively), while SABA overuse was similar in individuals with both mild (9–32%) and moderate-to-severe (8–31%) asthma in the other European countries.ConclusionsThe findings of this study from the SABINA program show that SABA overuse (at least three canisters per year) is common across Europe, despite the different healthcare and reimbursement policies of each country.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Lungmedicin och allergi0 (SwePub)302192 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Respiratory Medicine and Allergy0 (SwePub)302192 hsv//eng
653 a Europe
653 a Overreliance
653 a Prescription
653 a Public health
653 a Short-acting beta2-agonist
7001 a Menzies-Gow, Andrewu Royal Brompton Hosp, Lung Div, London, England4 aut
7001 a Nan, Cassandrau AstraZeneca, Biopharmaceut Med, Gothenburg, Sweden4 aut
7001 a Nuevo, Javieru AstraZeneca, Biopharmaceut Med, Serrano Galvache 56, Madrid 28033, Spain4 aut
7001 a Papi, Albertou Univ Ferrara, Dept Med Sci, Ferrara, Italy4 aut
7001 a Quint, Jennifer K.u Imperial Coll London, Natl Heart & Lung Inst, Resp Epidemiol Occupat Med & Publ Hlth, London, England4 aut
7001 a Quirce, Santiagou La Paz Univ Hosp, Dept Allergy, Madrid, Spain; CIBER Resp Dis CIBERES, Madrid, Spain4 aut
7001 a Vogelmeier, Claus F.u Philipps Univ Marburg, Univ Med Ctr Giessen & Marburg, Dept Med Pulm & Crit Care Med, Marburg, Germany; German Ctr Lung Res DZL, Marburg, Germany4 aut
7102 a Uppsala universitetb Lung- allergi- och sömnforskning4 org
7730 t Advances in Therapyd : Springer Science and Business Media LLCg 37:3, s. 1124-1135q 37:3<1124-1135x 0741-238Xx 1865-8652
8564 u https://doi.org/10.1007/s12325-020-01233-0y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1503214/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://link.springer.com/content/pdf/10.1007/s12325-020-01233-0.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-425647
8564 8u https://doi.org/10.1007/s12325-020-01233-0

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy